Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder
Efficacy outcomes are only informative to the extent that they are validated. We examined the measurement properties of efficacy measures from the phase III ("RECONNECT") bremelanotide trials for hypoactive sexual desire disorder (HSDD) in women. ...
Spielmans GI, Ellefson EM — Journal of sex research
An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder
Female sexual response implies a deep intertwining between psychosocial and neurobiological mediators. Regulation of central melanocortin signaling may enhance sexual desire. In premenopausal women with hypoactive sexual desire disorder (HSDD), me...
Cipriani S, Alfaroli C, Maseroli E et al. — Expert opinion on pharmacotherapy
Safety Profile of Bremelanotide Across the Clinical Development Program
Background: Bremelanotide, a melanocortin receptor agonist, is Food and Drug Administration (FDA)-approved for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. Methods: Review of bremelanotide's sa...
Clayton AH, Kingsberg SA, Portman D et al. — Journal of women's health (2002)
Medical Treatment of Female Sexual Dysfunction
Female sexual dysfunction (FSD) comprises multiple overlapping sexual disorders with a multifaceted cause within the frame of the biopsychosocial model. Health care providers can screen for FSD according to their level of expertise and deliver at ...
Nappi RE, Tiranini L, Martini E et al. — The Urologic clinics of North America
The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women
Hypoactive sexual desire disorder (HSDD) is a common female sexual dysfunction and is estimated to affect approximately 10% of women in the United States. It has been suggested that HSDD is associated with an imbalance of hormone and neurotransmit...
Pfaus JG, Sadiq A, Spana C et al. — CNS spectrums
Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide
Background: Hypoactive sexual desire disorder (HSDD), the most prevalent female sexual dysfunction, is characterized as persistent diminished desire for sexual activity accompanied by distress. The efficacy and safety of bremelanotide, a melanocor...
Simon JA, Kingsberg SA, Portman D et al. — Journal of women's health (2002)
Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women
Kingsberg et al. described results from two 24-week Phase III trials of bremelanotide for treating hypoactive sexual desire disorder (HSDD) in women. 72.72% of protocol-listed outcomes were not reported by Kingsberg et al., who provided results of...
Spielmans GI — Journal of sex research
Bremelanotide: First Approval
Bremelanotide (Vyleesi™) is a melanocortin receptor agonist recently approved in the USA for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire tha...
Dhillon S, Keam SJ — Drugs
An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist
Melanocortins affect multiple physiological responses, including sexual behaviors. Bremelanotide is a synthetic peptide melanocortin analog of alpha-melanocyte-stimulating hormone that is an agonist at melanocortin receptors MC3R and MC4R.
Diamond LE, Earle DC, Heiman JR et al. — The journal of sexual medicine
PT-141 Palatin
Palatin, under license from Competitive Technology, is developing the peptide PT-141, a synthetically modified analog of PT-14, as a nasal spray for the potential treatment of erectile dysfunction (ED) and female sexual dysfunction. In September 2...
Hedlund P — Current opinion in investigational drugs (London, England : 2000)